Personal information

Websites & social links

https://www.linkedin.com/in/henrykaophd

Activities

Collapse all

Employment (4)

Roche (Switzerland): Basel, CH

2017 to present | Group Head, Biomarker Sciences (Pharma Research and Early Development)
Employment
Source: Self-asserted source
Henry Kao

Bristol Myers Squibb Co: Princeton, NJ, US

2013 to 2017 (Discovery Oncology and Translational Research)
Employment
Source: Self-asserted source
Henry Kao

Lundbeck (Denmark): Copenhagen, DK

2010 to 2013 | Senior Scientist (Neuroinflammation Biology)
Employment
Source: Self-asserted source
Henry Kao

Allergan Foundation: Irvine, CA, US

2008 to 2010 | Scientist, Immunology
Employment
Source: Self-asserted source
Henry Kao

Education and qualifications (2)

Washington University in St Louis: St Louis, MO, US

Postdoctoral Fellow (Pathology & Immunology)
Qualification
Source: Self-asserted source
Henry Kao

University of Pittsburgh: Pittsburgh, Pennsylvania, US

PhD (Department of Immunology)
Education
Source: Self-asserted source
Henry Kao

Works (1)

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies

Clinical Cancer Research
2024-04-15 | Journal article
DOI: 10.1158/1078-0432.CCR-23-1530
Contributors: Michael A. Cannarile; Vaios Karanikas; Bernhard Reis; Christoph Mancao; Eleni Lagkadinou; Dominik Rüttinger; Natascha Rieder; Franclim R. Ribeiro; Henry Kao; Sebastian Dziadek et al.
Source: check_circle
Crossref

Peer review (4 reviews for 1 publication/grant)

Review activity for Journal for immunotherapy of cancer. (4)
How many people are using ORCID?